JP2024519188A - 含窒素複素環系化合物、その調製方法及びその医薬的応用 - Google Patents

含窒素複素環系化合物、その調製方法及びその医薬的応用 Download PDF

Info

Publication number
JP2024519188A
JP2024519188A JP2024515728A JP2024515728A JP2024519188A JP 2024519188 A JP2024519188 A JP 2024519188A JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024519188 A JP2024519188 A JP 2024519188A
Authority
JP
Japan
Prior art keywords
group
general formula
compound
salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519188A5 (https=
JPWO2022247816A5 (https=
Inventor
心 李
▲懐▼▲徳▼ 董
国▲棟▼ 蔡
峰 ▲賀▼
▲維▼康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024519188A publication Critical patent/JP2024519188A/ja
Publication of JP2024519188A5 publication Critical patent/JP2024519188A5/ja
Publication of JPWO2022247816A5 publication Critical patent/JPWO2022247816A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024515728A 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用 Pending JP2024519188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110565410.0 2021-05-24
CN202110565410 2021-05-24
CN202110694022 2021-06-22
CN202110694022.2 2021-06-22
CN202110856289 2021-07-28
CN202110856289.7 2021-07-28
CN202210198679 2022-03-02
CN202210198679.4 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2024519188A true JP2024519188A (ja) 2024-05-08
JP2024519188A5 JP2024519188A5 (https=) 2025-06-03
JPWO2022247816A5 JPWO2022247816A5 (https=) 2025-06-03

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515728A Pending JP2024519188A (ja) 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US20240287094A1 (https=)
EP (1) EP4349836A4 (https=)
JP (1) JP2024519188A (https=)
KR (1) KR20240012437A (https=)
CN (1) CN117177971A (https=)
AU (1) AU2022280845A1 (https=)
BR (1) BR112023022496A2 (https=)
CA (1) CA3219858A1 (https=)
MX (1) MX2023013890A (https=)
TW (1) TW202313630A (https=)
WO (1) WO2022247816A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
FI4497438T3 (fi) 2022-04-28 2025-10-20 Xinthera Inc Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
CN120035596A (zh) * 2022-11-23 2025-05-23 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法
AU2024286996A1 (en) 2023-06-08 2026-01-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for formamide compounds
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521698A (ja) * 2002-03-26 2005-07-21 藤沢薬品工業株式会社 新規な三環式化合物
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
JP2024514223A (ja) * 2021-04-19 2024-03-28 シンセラ, インコーポレイテッド Parp1阻害薬及びその使用
JP2025516367A (ja) * 2022-05-07 2025-05-27 メッドシャイン ディスカバリー インコーポレイテッド Parp1を選択的に阻害するフルオロキノキサリノン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
JP7469304B2 (ja) * 2018-11-16 2024-04-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Parpインヒビタを含む医薬組成物
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521698A (ja) * 2002-03-26 2005-07-21 藤沢薬品工業株式会社 新規な三環式化合物
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのキノリノン誘導体
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
JP2024514223A (ja) * 2021-04-19 2024-03-28 シンセラ, インコーポレイテッド Parp1阻害薬及びその使用
JP2025516367A (ja) * 2022-05-07 2025-05-27 メッドシャイン ディスカバリー インコーポレイテッド Parp1を選択的に阻害するフルオロキノキサリノン誘導体

Also Published As

Publication number Publication date
CA3219858A1 (en) 2022-12-01
BR112023022496A2 (pt) 2024-01-16
EP4349836A1 (en) 2024-04-10
US20240287094A1 (en) 2024-08-29
EP4349836A4 (en) 2024-10-30
AU2022280845A1 (en) 2023-12-14
CN117177971A (zh) 2023-12-05
TW202313630A (zh) 2023-04-01
WO2022247816A1 (zh) 2022-12-01
KR20240012437A (ko) 2024-01-29
MX2023013890A (es) 2023-12-11

Similar Documents

Publication Publication Date Title
JP2024519188A (ja) 含窒素複素環系化合物、その調製方法及びその医薬的応用
EP4361157A1 (en) Fused tetracyclic compound, preparation method therefor and application thereof in medicine
CN119365465A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
CN117203207A (zh) 桥环类化合物、其制备方法及其在医药上的应用
CN115605479B (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN115385937A (zh) 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
JP7781059B2 (ja) ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
WO2024046420A1 (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
TW202246260A (zh) 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN113004303A (zh) 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
CN113135942B (zh) 稠合嘧啶类衍生物、其制备方法及其在医药上的应用
EA051431B1 (ru) Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1
WO2021143821A1 (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
HK40070277A (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
HK40070277B (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN114907406A (zh) 嘧啶衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224